AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Ingevity Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

On 31 Jul 2025, Corteva Inc. (CTVA) director Nayaki R. Nayyar acquired 450.5754 common-stock units at a reference price of $72.13 through the company’s Stock Accumulation and Deferred Compensation Plan for Directors. The transaction, coded “A,� reflects a deferral of board fees rather than an open-market buy. After including 72.7656 shares gained via dividend reinvestment, the director’s total beneficial ownership rises to 32,279.0821 shares. No dispositions or derivative securities were reported, and ownership remains direct.

Il 31 luglio 2025, la direttrice di Corteva Inc. (CTVA), Nayaki R. Nayyar, ha acquisito 450,5754 unità di azioni ordinarie a un prezzo di riferimento di 72,13$ tramite il Piano di Accumulo Azionario e Compensazione Differita per i Direttori della società. L’operazione, contrassegnata con il codice “A�, rappresenta un differimento delle commissioni del consiglio piuttosto che un acquisto sul mercato aperto. Includendo inoltre 72,7656 azioni ottenute tramite il reinvestimento dei dividendi, la proprietà totale effettiva della direttrice sale a 32.279,0821 azioni. Non sono state segnalate cessioni o strumenti derivati, e la proprietà rimane diretta.

El 31 de julio de 2025, la directora de Corteva Inc. (CTVA), Nayaki R. Nayyar, adquirió 450,5754 unidades de acciones comunes a un precio de referencia de 72,13$ a través del Plan de Acumulación de Acciones y Compensación Diferida para Directores de la empresa. La transacción, codificada como “A�, refleja un aplazamiento de las tarifas del consejo en lugar de una compra en el mercado abierto. Tras incluir 72,7656 acciones obtenidas mediante la reinversión de dividendos, la propiedad total beneficiaria de la directora aumenta a 32.279,0821 acciones. No se reportaron disposiciones ni valores derivados, y la propiedad sigue siendo directa.

2025ë…� 7ì›� 31ì�, Corteva Inc.(CTVA) ì´ì‚¬ Nayaki R. NayyarëŠ� 회사ì� ì´ì‚¬ìš� ì£¼ì‹ ì ë¦½ ë°� ì´ì—° ë³´ìƒ ê³„íšì� 통해 기준 ê°€ê²� $72.13ì—� 450.5754 보통ì£� 단위ë¥� ì·¨ë“했습니다. “Aâ€� 코드ë¡� 표시ë� ì� 거래ëŠ� 공개 시장 매수가 아니ë� ì´ì‚¬íš� ìˆ˜ìˆ˜ë£Œì˜ ì´ì—°ì� ë°˜ì˜í•©ë‹ˆë‹�. 배당ê¸� 재투ìžë¥¼ 통해 ì–»ì€ 72.7656 주를 í¬í•¨í•˜ë©´ ì´ì‚¬ì� ì´� 실질 소유 주ì‹ì€ 32,279.0821 주로 ì¦ê°€í•©ë‹ˆë‹�. 처분ì´ë‚˜ íŒŒìƒ ì¦ê¶Œ ë³´ê³ ëŠ� 없었으며, ì†Œìœ ê¶Œì€ ì§ì ‘ 소유 ìƒíƒœë¥� 유지합니ë‹�.

Le 31 juillet 2025, la directrice de Corteva Inc. (CTVA), Nayaki R. Nayyar, a acquis 450,5754 unités d’actions ordinaires à un prix de référence de 72,13 $ dans le cadre du Plan d’Accumulation d’Actions et de Rémunération Différée pour les Administrateurs de la société. La transaction, codée « A », reflète un report des frais du conseil d’administration plutôt qu’un achat sur le marché ouvert. Après avoir inclus 72,7656 actions obtenues par réinvestissement des dividendes, la propriété bénéficiaire totale de la directrice s’élève à 32 279,0821 actions. Aucune cession ni instrument dérivé n’a été signalé, et la propriété reste directe.

Am 31. Juli 2025 erwarb die Direktorin von Corteva Inc. (CTVA), Nayaki R. Nayyar, 450,5754 Stammaktieneinheiten zu einem Referenzpreis von 72,13$ über den Aktienansammlungs- und aufgeschobenen Vergütungsplan für Direktoren des Unternehmens. Die Transaktion, mit dem Code „A� gekennzeichnet, stellt eine Aufschiebung der Vorstandsvergütungen dar und keinen Kauf am offenen Markt. Nach Einbeziehung von 72,7656 Aktien, die durch Dividendenreinvestition erworben wurden, erhöht sich das gesamte wirtschaftliche Eigentum der Direktorin auf 32.279,0821 Aktien. Es wurden keine Veräußerungen oder derivativen Wertpapiere gemeldet, und das Eigentum bleibt direkt.

Positive
  • Director increased beneficial ownership by 450.6 shares, reinforcing insider alignment.
  • Total holdings now at 32,279 shares indicates a meaningful personal stake on the board.
Negative
  • Acquisition stems from automatic compensation deferral, not discretionary open-market buying, weakening the bullish signal.
  • Dollar value (~$32k) is negligible relative to Corteva’s size, so market impact is minimal.

Insights

TL;DR: Small, plan-based insider acquisition—signal is modest and neutral for valuation.

The purchase increases the director’s stake by only 1.4 % and is tied to automatic fee deferral, limiting its informational value. Still, continued share accumulation maintains alignment between the board and investors. Given Corteva’s multibillion-dollar market cap, the $32 k transaction is immaterial and unlikely to affect trading dynamics.

Il 31 luglio 2025, la direttrice di Corteva Inc. (CTVA), Nayaki R. Nayyar, ha acquisito 450,5754 unità di azioni ordinarie a un prezzo di riferimento di 72,13$ tramite il Piano di Accumulo Azionario e Compensazione Differita per i Direttori della società. L’operazione, contrassegnata con il codice “A�, rappresenta un differimento delle commissioni del consiglio piuttosto che un acquisto sul mercato aperto. Includendo inoltre 72,7656 azioni ottenute tramite il reinvestimento dei dividendi, la proprietà totale effettiva della direttrice sale a 32.279,0821 azioni. Non sono state segnalate cessioni o strumenti derivati, e la proprietà rimane diretta.

El 31 de julio de 2025, la directora de Corteva Inc. (CTVA), Nayaki R. Nayyar, adquirió 450,5754 unidades de acciones comunes a un precio de referencia de 72,13$ a través del Plan de Acumulación de Acciones y Compensación Diferida para Directores de la empresa. La transacción, codificada como “A�, refleja un aplazamiento de las tarifas del consejo en lugar de una compra en el mercado abierto. Tras incluir 72,7656 acciones obtenidas mediante la reinversión de dividendos, la propiedad total beneficiaria de la directora aumenta a 32.279,0821 acciones. No se reportaron disposiciones ni valores derivados, y la propiedad sigue siendo directa.

2025ë…� 7ì›� 31ì�, Corteva Inc.(CTVA) ì´ì‚¬ Nayaki R. NayyarëŠ� 회사ì� ì´ì‚¬ìš� ì£¼ì‹ ì ë¦½ ë°� ì´ì—° ë³´ìƒ ê³„íšì� 통해 기준 ê°€ê²� $72.13ì—� 450.5754 보통ì£� 단위ë¥� ì·¨ë“했습니다. “Aâ€� 코드ë¡� 표시ë� ì� 거래ëŠ� 공개 시장 매수가 아니ë� ì´ì‚¬íš� ìˆ˜ìˆ˜ë£Œì˜ ì´ì—°ì� ë°˜ì˜í•©ë‹ˆë‹�. 배당ê¸� 재투ìžë¥¼ 통해 ì–»ì€ 72.7656 주를 í¬í•¨í•˜ë©´ ì´ì‚¬ì� ì´� 실질 소유 주ì‹ì€ 32,279.0821 주로 ì¦ê°€í•©ë‹ˆë‹�. 처분ì´ë‚˜ íŒŒìƒ ì¦ê¶Œ ë³´ê³ ëŠ� 없었으며, ì†Œìœ ê¶Œì€ ì§ì ‘ 소유 ìƒíƒœë¥� 유지합니ë‹�.

Le 31 juillet 2025, la directrice de Corteva Inc. (CTVA), Nayaki R. Nayyar, a acquis 450,5754 unités d’actions ordinaires à un prix de référence de 72,13 $ dans le cadre du Plan d’Accumulation d’Actions et de Rémunération Différée pour les Administrateurs de la société. La transaction, codée « A », reflète un report des frais du conseil d’administration plutôt qu’un achat sur le marché ouvert. Après avoir inclus 72,7656 actions obtenues par réinvestissement des dividendes, la propriété bénéficiaire totale de la directrice s’élève à 32 279,0821 actions. Aucune cession ni instrument dérivé n’a été signalé, et la propriété reste directe.

Am 31. Juli 2025 erwarb die Direktorin von Corteva Inc. (CTVA), Nayaki R. Nayyar, 450,5754 Stammaktieneinheiten zu einem Referenzpreis von 72,13$ über den Aktienansammlungs- und aufgeschobenen Vergütungsplan für Direktoren des Unternehmens. Die Transaktion, mit dem Code „A� gekennzeichnet, stellt eine Aufschiebung der Vorstandsvergütungen dar und keinen Kauf am offenen Markt. Nach Einbeziehung von 72,7656 Aktien, die durch Dividendenreinvestition erworben wurden, erhöht sich das gesamte wirtschaftliche Eigentum der Direktorin auf 32.279,0821 Aktien. Es wurden keine Veräußerungen oder derivativen Wertpapiere gemeldet, und das Eigentum bleibt direkt.

falseIngevity Corp000165347700016534772025-08-042025-08-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________________________________________ 
FORM 8-K
_______________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

August 4, 2025
Date of Report (date of earliest event reported)
__________________________________________________________________________
ingevitylogorgba11.jpg
INGEVITY CORPORATION
(Exact name of registrant as specified in its charter)
__________________________________________________________________________ 
Delaware001-3758647-4027764
(State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
4920 O'Hear Avenue Suite 400North CharlestonSouth Carolina29405
(Address of principal executive offices) (Zip code)


Registrant’s telephone number, including area code: 843-740-2300

Not Applicable
(Former name or former address, if changed since last report)
_____________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock ($0.01 par value)NGVTNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Acto
_____________________________________________________________________________________________________



ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On August 4, 2025, Ingevity Corporation ("Ingevity") announced its preliminary financial results for the three and six months ended June 30, 2025 which are attached as Exhibit 99.1 to this Current Report on Form 8-K.
Please refer to our website for additional information regarding Ingevity. Periodically we may provide other information on the investor relations page of our website. Interested parties are encouraged to visit Ingevity's website to view such other information including Ingevity slide presentations.
The information contained in Item 2.02 of this report, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.
Exhibit No.Description of Exhibit
99.1
Press release dated August 4, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INGEVITY CORPORATION
(Registrant)
By:/S/ MARY DEAN HALL
Mary Dean Hall
Executive Vice President and Chief Financial Officer
Date: August 4, 2025

FAQ

What did Corteva (CTVA) director Nayaki Nayyar acquire on 31 July 2025?

450.5754 common-stock units under the director deferred-compensation plan.

At what price were the Corteva stock units credited?

They were valued at $72.13 per share equivalent.

How many Corteva shares does the director now hold?

Total beneficial ownership stands at 32,279.0821 shares.

Was this an open-market purchase?

No. The shares were issued via automatic fee deferral, not bought on the market.

Did the Form 4 report any derivative securities or dispositions?

No derivative positions or share sales were disclosed.
Ingevity Corp

NYSE:NGVT

NGVT Rankings

NGVT Latest News

NGVT Latest SEC Filings

NGVT Stock Data

1.47B
35.99M
1.21%
103.39%
3.32%
Specialty Chemicals
Chemicals & Allied Products
United States
NORTH CHARLESTON